LNTH Stock Analysis — Lantheus Holdings
Sector: Healthcare
AI Verdict
LNTH trades at 15.4x next year's earnings with 70.0% EPS growth expected, so it's cheap for the growth you're getting if their regulatory moat keeps competitors at bay.
Competitive Moat
Lantheus specializes in diagnostic and therapeutic medical imaging agents, with a defensible position built on regulatory approvals and established relationships with hospitals and imaging centers. Its portfolio includes proprietary radiopharmaceuticals that are difficult for competitors to replicate due to clinical data requirements and distribution logistics.
Summary
LNTH is on watch as analysts expect a 70.0% jump in earnings per share over the next year.
Where It Stands
LNTH trades at 15.4x next year's earnings, a discount to the healthcare sector median of 22x, while trailing P/E is 26.1x and revenue growth is nearly flat at 0.6%.
Key Metrics
- Trailing P/E: 26.1x
- Forward P/E: 15.4x
- PEG Ratio: 0.37
- Earnings Growth: +0.7%
- Revenue Growth: +0.0%
- 52-Week High: $95.86
- 52-Week Low: $47.25
Analyst Consensus
16 Buy · 3 Hold · 0 Sell (19 analysts)
Bull Case
With forward EPS growth forecast at 70.0%, the 15.4x forward P/E is cheap for the growth on offer if execution holds.
Bear Case
If the forward P/E reverts to the sector median of 22x without the expected growth materializing, the stock could see a sharp pullback as the market reprices flat revenue momentum.
Catalyst to Watch
Watch for upcoming clinical trial results or FDA decisions on new imaging agents, as positive outcomes could validate the aggressive earnings growth forecast.